Insider Selling: LeMaitre Vascular, Inc. (NASDAQ:LMAT) Director Sells 6,561 Shares of Stock

Key Points

• John A. Roush, Director of LeMaitre Vascular, sold 6,561 shares at an average price of $92.55, totaling approximately $607,220, representing a 69.23% decrease in his ownership.
• LeMaitre Vascular recently reported $0.60 earnings per share for the last quarter, exceeding analysts' expectations and marking a 15.0% revenue increase year-over-year.
• The company announced a quarterly dividend of $0.20 per share, indicating an annualized yield of 0.8% and a payout ratio of 38.83%.

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) Director John A. Roush sold 6,561 shares of the company's stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $92.55, for a total value of $607,220.55. Following the transaction, the director directly owned 2,916 shares of the company's stock, valued at $269,875.80. This trade represents a 69.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

LeMaitre Vascular Stock Performance

LMAT stock traded up $0.78 on Wednesday, reaching $95.16. The company's stock had a trading volume of 21,578 shares, compared to its average volume of 188,963. LeMaitre Vascular, Inc. has a 52 week low of $71.42 and a 52 week high of $109.58. The company has a market capitalization of $2.15 billion, a P/E ratio of 46.24, a price-to-earnings-growth ratio of 2.38 and a beta of 0.79. The firm has a fifty day moving average of $83.82 and a two-hundred day moving average of $86.52. The company has a debt-to-equity ratio of 0.46, a current ratio of 13.96 and a quick ratio of 11.74.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%. The business had revenue of $63.15 million during the quarter, compared to analyst estimates of $62.48 million. During the same period in the prior year, the company posted $0.52 EPS. The business's revenue for the quarter was up 15.0% compared to the same quarter last year. As a group, analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 4th. Investors of record on Thursday, August 21st will be issued a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend is Thursday, August 21st. LeMaitre Vascular's dividend payout ratio is 38.83%.

Analyst Ratings Changes

Several equities analysts have recently commented on LMAT shares. Cantor Fitzgerald upped their target price on LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Barrington Research raised LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 target price for the company in a report on Wednesday, August 6th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $98.00.

Hedge Funds Weigh In On LeMaitre Vascular

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LMAT. Alliancebernstein L.P. lifted its position in LeMaitre Vascular by 6.0% in the fourth quarter. Alliancebernstein L.P. now owns 22,584 shares of the medical instruments supplier's stock worth $2,081,000 after purchasing an additional 1,287 shares during the period. Franklin Resources Inc. lifted its position in LeMaitre Vascular by 8.2% in the fourth quarter. Franklin Resources Inc. now owns 13,678 shares of the medical instruments supplier's stock worth $1,260,000 after purchasing an additional 1,032 shares during the period. Wells Fargo & Company MN lifted its position in LeMaitre Vascular by 8.8% in the fourth quarter. Wells Fargo & Company MN now owns 28,153 shares of the medical instruments supplier's stock worth $2,594,000 after purchasing an additional 2,274 shares during the period. Bank of Montreal Can lifted its position in LeMaitre Vascular by 8.3% in the fourth quarter. Bank of Montreal Can now owns 2,926 shares of the medical instruments supplier's stock worth $270,000 after purchasing an additional 223 shares during the period. Finally, Invesco Ltd. lifted its position in LeMaitre Vascular by 50.5% in the fourth quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier's stock worth $16,124,000 after purchasing an additional 58,720 shares during the period. 84.64% of the stock is owned by institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.